Patient case studies reveal results worth celebrating

Clinical background and photographs from case studies of patients treated with Wynzora

Patient with lower leg psoriasis1

Patient: 38-year-old male

Initial exam: January 21, 2022

Affected area: Lower leg

Treatment approach:

  • Patient started Wynzora treatment once daily on January 21, 2022 and was advised to treat as directed until clear
  • Follow-up visits from initial diagnosis at 4-week intervals
Patient with lower leg psoriasis baseline Patient with lower leg psoriasis after 4 weeks of Wynzora treatment Patient with lower leg psoriasis after 8 weeks of Wynzora treatment

Patient with scalp psoriasis1

Patient: 51-year-old male

Initial exam: 2015

Affected area: Scalp, back, and extremities (upper and lower)

Current exam:

  • Psoriasis plaques of the trunk and extremities are well-controlled with Ilumya® (tildrakizumab-asmn)*
  • Psoriasis plaques involving the right and left posterior scalp persist

Treatment approach:

  • Patient started Wynzora treatment once daily on January 31, 2022
  • Treatment was discontinued after 2 weeks due to clearance of psoriasis plaques on the scalp
Patient with scalp psoriasis baseline Patient with scalp psoriasis after 1 week of Wynzora treatment Patient with scalp psoriasis after 2 weeks of Wynzora treatment


Important safety information

INDICATION: Wynzora® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. ADVERSE EVENTS: In the pivotal trial, the most common adverse reactions (≥1%) were: upper respiratory infection (7%), headache (2%), and application site infection (1%). WARNINGS AND PRECAUTIONS: For topical use only. Patients should not use more than 100g of Wynzora® Cream per week. Do not use near or in the mouth, eyes or intravaginally. Avoid using Wynzora® Cream on the face, groin or armpits, or if they have atrophy at the treatment site. Discontinue use once plaque psoriasis is under control or at 8 weeks. Do not use Wynzora® Cream with occlusive dressings. Hypercalcemia and hypercalciuria have been observed with topical use of calcipotriene. Wynzora® Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment. Wynzora® Cream may cause vision problems, including increasing the risk of cataracts and glaucoma. It is not known if Wynzora® Cream may harm your unborn baby. Breastfeeding women should not apply Wynzora® Cream directly to the nipple or areola; it is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see Full Prescribing Information for Wynzora.

You are encouraged to report side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Reference: 1. Data on File. MC2 Therapeutics.

pink close icon

Watch how PADTM Technology optimizes absorption of Cal and BDP3

Play button for Wynzora and PAD™ Technology mechanism of action video
Wynzora MOA video icon